Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed small cell lung cancer, meeting 1 of the following criteria:~  * Previously untreated metastatic or extensive disease~    * Malignant pleural effusion or multifocal lung disease is considered metastatic or extensive disease~   * Prior radiotherapy allowed~ * Recurrent disease~    * Limited, metastatic, or extensive disease~   * Relapsed after prior chemotherapy, excluding irinotecan hydrochloride~      * At least 90 days since prior chemotherapy~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 1 cm by physical examination or radiographic techniques~* Known brain metastases allowed~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* White Blood Cells \> 3,000/mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9.0 g/dL~* Bilirubin ≤ 1.5 mg/dL~* SGOT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No medical disease that, in the opinion of the investigator, would preclude study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 10 days since prior radiotherapy (including brain)~* No prior irinotecan hydrochloride~* At least 2 weeks since prior and no concurrent anticonvulsants~* No concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metastatic SCLC (Type: EXPERIMENTAL): Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
- Relapsed SCLC (Type: EXPERIMENTAL): Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).